You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DANTROLENE SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DANTROLENE SODIUM

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02829268 ↗ A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome Active, not recruiting National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 1/Phase 2 2017-01-01 Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions. There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.
NCT02829268 ↗ A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome Active, not recruiting National Institutes of Health (NIH) Phase 1/Phase 2 2017-01-01 Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions. There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.
NCT02829268 ↗ A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome Active, not recruiting Washington University School of Medicine Phase 1/Phase 2 2017-01-01 Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions. There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.
NCT03762109 ↗ The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery Recruiting Beth Israel Deaconess Medical Center Phase 2 2019-07-29 The purpose of this study is to determine whether administration of a non-centrally acting muscle relaxants will improve the Overall Benefit of Analgesia Score (OBAS), and Richmond Agitation Sedation Scale (RASS) scores in patients undergoing lumbar fusion.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DANTROLENE SODIUM

Condition Name

Condition Name for DANTROLENE SODIUM
Intervention Trials
Optic Nerve Atrophy 1
Wolfram Syndrome 1
Ataxia 1
Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DANTROLENE SODIUM
Intervention Trials
Wolfram Syndrome 1
Syndrome 1
Optic Atrophy 1
Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DANTROLENE SODIUM

Trials by Country

Trials by Country for DANTROLENE SODIUM
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DANTROLENE SODIUM
Location Trials
Massachusetts 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DANTROLENE SODIUM

Clinical Trial Phase

Clinical Trial Phase for DANTROLENE SODIUM
Clinical Trial Phase Trials
Phase 2 1
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DANTROLENE SODIUM
Clinical Trial Phase Trials
Active, not recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DANTROLENE SODIUM

Sponsor Name

Sponsor Name for DANTROLENE SODIUM
Sponsor Trials
National Institutes of Health (NIH) 1
Washington University School of Medicine 1
Beth Israel Deaconess Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DANTROLENE SODIUM
Sponsor Trials
Other 2
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.